The Director’s Update in the October 4, 2005 edition of the NCI Cancer Bulletin highlights some of the leadership changes at the National Cancer Institute (NCI) and how these changes will help NCI maintain its forward progress toward the 2015 goal to eliminate the suffering and death due to cancer by the year 2015.
NCI Director Dr. Andrew von Eschenbach started the article by stating:
>Last week brought with it an important change at the National Cancer Institute (NCI), with my appointment as interim commissioner of the Food and Drug Administration (FDA) by President Bush. And as I said at the time, I will maintain my position as NCI director and my ultimate commitment to the 2015 goal.
>To ensure that the many ambitious initiatives and programs we have launched to reach that goal continue to progress, Department of Health and Human Services Secretary Mike Leavitt has asked Dr. John Niederhuber, who recently came to NCI as deputy director for translational and clinical sciences, to serve as the NCI chief operating officer to handle much of the institute’s day-to-day management.
Dr. von Eschenbach closed his remarks by saying:
>While their missions may differ somewhat, NCI and FDA, along with the other government health agencies, share a common goal of improving public health. I am committed to leading FDA through this time of transition and fulfilling my responsibilities to NCI.
>Change is never easy, but with good people and a dedication to success, I have no doubt we can come through it for the better.